EXELIXIS, INC.
EXELIXIS, INC. (EXEL): 24 pipeline candidates · 10 upcoming catalysts · ~8 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
7.8 months
D/E 0.34 · 5% dilution
Lead: Approved
24 candidates
10 upcoming, next in ~413d
0 buys · 23 sells (180d)
A transparent, data-derived signal for EXELIXIS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$13.2B
Cash
$226.2M
Quarterly Burn
$339.5M
Runway
7.8 mo
Revenue
$610.8M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (24 candidates)
| Drug | Phase |
|---|---|
| AB521 | Phase 1 |
| abiraterone | Phase 3 |
| CABOMETYX | Approved |
| CABOMETYX (cabozantinib) | Approved |
| cabozantinib | Phase 3 |
| COMETRIQ | Approved |
| COMETRIQ (cabozantinib) | Approved |
| COTELLIC | Approved |
| COTELLIC (cobimetinib) | Approved |
| esomeprazole magnesium | Approved |
Showing 10 of 24 candidates. Sign up for full pipeline.
Upcoming Catalysts (10)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Frequently asked questions
How many drug candidates are in EXELIXIS, INC.'s pipeline?
EXELIXIS, INC. (EXEL) has 24 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is EXELIXIS, INC.'s lead drug candidate?
EXELIXIS, INC.'s most advanced tracked candidate is AB521 (Phase 1) for Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors.
What is EXELIXIS, INC.'s next catalyst?
EXELIXIS, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: SUPREP BOWEL PREP KIT" — expected August 5, 2027.
What is EXELIXIS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, EXELIXIS, INC. has approximately 7.8 months of cash runway.
What is EXELIXIS, INC.'s market capitalization?
EXELIXIS, INC.'s market capitalization is approximately $13.2B.
Get the full picture on EXELIXIS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.